Eisai Co., Ltd. (Headquarters:
Tokyo, President and CEO: Haruo Naito) and Eisai Inc.
(Headquarters: New Jersey, Chairman and CEO: Hajime Shimizu)
today announce that they received court decisions on
ANDA-related summary judgment motions for Aciphex (Active
Ingredient Name: rabeprazole sodium, Product Name in Japan:
Pariet) on October 6, 2006 (U.S. Eastern time).
The Southern District Court of New York granted Eisai’s
summary judgment motion confirming the validity of the
Aciphex composition of matter patent in its ruling. The
Court reserved ruling on the enforceability arguments until
after trial. Eisai looks forward to the trial and will
vigorously defend its Aciphex patent in order to protect
the company’s interests.
Related Results
Eisai bolsters its sales team to promote CNS products, increase independence
Eisai, Janssen educate consumers on acid reflux
Japan Drug Firm Eisai Posts Increased Sales, Profits for Fiscal First Half.
Prevacid held slight lead in proton pump inhibitor sales to retailers for 200…
“Ac”cident potential
Aciphex has been shown to have a rapid onset of action
and a reliable inhibitory effect on acid secretion related
to duodenal ulcers and gastroesophageal reflux disease,
which are confirmed in clinical studies. Aciphex was
launched in the U.S. in 1999 and is currently marketed
worldwide.
About Aciphex
Aciphex has a well-established safety profile. The most
common side effect possibly related to Aciphex is
headache. Symptom relief does not rule out other serious
stomach conditions. Patients on Warfarin (such as
Coumadin) may need to be monitored more closely by their
doctor. For more information, visit www.aciphex.com or
www.eisai.com .
Contacts:
Corporate Communications Department
Eisai Co., Ltd.
TEL: 81-3-3817-5120
Cathy Pollini
Corporate Planning and Communications
Eisai Inc.
TEL: 1-201-287-2052